Health Durvalumab and Chemoradiotherapy Show No Survival Benefit in NSCLC The phase 3 EA5181 trial has concluded that concurrent treatment with durvalumab (Imfinzi) and chemoradiotherapy does not improve survival rates in patients with unresectable,... Editorial11 hours ago